Search

Researchers in radiology at Memorial Sloan Kettering continue to assess multiple imaging methods in the quest to improve treatment options and success rates for patients with biliary cancers such as cholangiocarcinoma.

… Wednesday, December 7, 2016 Imaging plays a central role in the management of biliary cancers and, while multidetector computed tomography remains the method of choice for imaging of most hepatobiliary tumors, researchers in radiology at Memorial Sloan Kettering continue to asses other methods in the

Learn about the Green Bronx Machine, a program that allows students to benefit their community by growing and distributing fresh food.

… Friday, June 28, 2019 Summary MSK’s Immigrant Health and Cancer Disparities Service has partnered with a local organization called the Green Bronx Machine to provide fresh fruits and vegetables to underserved people with cancer in New York City. Inside a renovated 100-year-old library within the South

Discover how easy it is to donate blood — and the real impact your donation makes.

… Friday, July 28, 2023 VIDEO | 00:35 Diary of A First-Time Blood Donor Watch MSK employee Meredith Begley go through the process of donating blood. Don't worry — there are no needles in this video! Video Details The more time I spend working at Memorial Sloan Kettering Cancer Center, the more I learn

Researchers have found two gene mutations that many exceptional responders to ipilimumab have in common.

… Wednesday, September 28, 2016 Summary A review of nearly 200 patients receiving the immunotherapy ipilimumab for the treatment of melanoma has found two gene mutations that are linked to exceptional response to the drug. Highlights Exceptional responders experience long-term remission or even are cured

Memorial Sloan Kettering Cancer Center has appointed Gilles Salles, MD, PhD, Chief of the Lymphoma Service, Division of Hematologic Malignancies.

… Friday, November 12, 2021 Memorial Sloan Kettering Cancer Center (MSK) has appointed Gilles Salles, MD, PhD , as Chief of the Lymphoma Service, Division of Hematologic Malignancies. He succeeds Anas Younes, MD. Dr. Salles received his MD and PhD from the Université Claude Bernard Lyon and completed a

High-risk neuroblastoma cells harbor distinguishing molecular signatures, according to recent research.

… Friday, August 2, 2019 High-risk neuroblastoma cells harbor distinguishing molecular signatures, according to research that physician-scientists at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine published recently in the journal Neoplasia. These unique characteristics distinguish neuroblastoma

Discover how MSK Monmouth is making an impact in Middletown, New Jersey.

… Wednesday, December 13, 2017 In the year since MSK Monmouth opened its doors in Middletown, New Jersey, the facility has become a vital part of the community. VIDEO | 03:45 Meet the MSK Monmouth Care Team Hear about the benefits of receiving surgery, treatment and rehabilitation close to home. Video

Meet Leslie Ballantyne, Vice President of HR Legal and Regulatory Affairs at Memorial Sloan Kettering.

… Friday, April 2, 2021 Leslie Ballantyne says Eleanor Roosevelt has inspired her both personally and professionally. “The breadth of her accomplishments and commitment to her causes is just astounding,” says MSK’s Vice President of HR Legal and Regulatory Affairs. “She was ahead of her time in being an

A two-drug combination may hold the key to overcoming resistance in an aggressive form of non-Hodgkin lymphoma.

… Friday, November 16, 2018 Summary A promising target in the treatment of diffuse large B cell lymphoma (DLBCL) is a protein called BCL2. Drugs that inhibit this protein have been disappointing so far. Researchers have now discovered why DLBCL often proves resistant to this treatment. They have shown

A new era in the treatment of MIBC is on the horizon, with the combination of enfortumab vedotin plus pembrolizumab poised to become the new standard of care in the perioperative treatment of cisplatin-ineligible or cisplatin-refusing patients. MSK’s David Aggen, MD, discusses this, and what new treatment approaches physicians and scientists at MSK are now testing.

… Thursday, November 13, 2025 A Q&A with  David Aggen, MD, PhD , MSK Genitourinary Medical Oncologist and Cellular Therapist A new era in the treatment of muscle-invasive bladder cancer (MIBC) is on the horizon, with the combination of enfortumab vedotin plus pembrolizumab poised to become the new standard